| 临床参数 | 治疗效果 | P | |||
| 治愈(%) | 有效(%) | 无效 | |||
| 性别 |
|
| 0.758 | ||
| 男 | 29 | 13 (44.8%) | 7 (24.1%) | 9 (31.0%) | |
| 女 | 51 | 26 (51.0%) | 13 (25.5%) | 12 (23.5%) | |
| 年龄 |
|
| 0.117 | ||
| 0~3 | 46 | 19 (41.3%) | 11 (23.9%) | 16 (34.8%) | |
| 3~6 | 34 | 20 (58.8%) | 9 (26.5%) | 5 (14.7%) | |
| 治疗方式 |
|
|
|
| 0.003* |
| 非选择性β受体阻滞剂 | 20 | 5 (25.0%) | 11 (55.0%) | 4 (20.0%) | |
| 32P敷贴 | 20 | 9 (45.0%) | 2 (10.0%) | 9 (45.0%) | |
| 马来酸噻吗洛尔外敷 | 20 | 11 (55.0%) | 3 (15.0%) | 6 (30.0%) | |
| 32P敷贴联合马来酸噻吗洛尔外敷 | 20 | 14 (70.0%) | 4 (20.0%) | 2 (10.0%) | |